This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Kyowa Hakko Kirin Co., Ltd.
Drug Names(s): granisetron transdermal delivery system, JB-001, SP-01
Description: Sancuso is a transdermal patch that delivers granisetron, a 5HT3 receptorantagonist, steadily into the bloodstream for up to seven days.
Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge, inducing vomiting.
ProStrakan and LGLS
In August 2007, ProStrakan announced that it signed an exclusive distribution agreement with LG Life Sciences (LGLS) for Sancuso. Under the terms of the agreement, ProStrakan will receive upfront and milestone payments, subject to the achievement of certain approvals and sales targets, of up to $6 million. ProStrakan will exclusively supply Sancuso to LGLS and will receive an undisclosed royalty rate on sales generated in South Korea by LGLS.
ProStrakan and Solasia
In May 2008, ProStrakan and JapanBridge K.K. announced an exclusive licence granted to JapanBridge for Sancuso in Japan, People's Republic of China, Taiwan, Singapore and Malaysia. The company changed its name from JapanBridge K.K. to Solasia Pharma K.K. in October 2008.
In August 2010, ProStrakan announced that it received notification that Solasia Pharma K.K. is handing back the right to market and sell Sancuso in Japan, but that it will retain its rights in the other...See full deal structure in Biomedtracker
Partners: Solasia Pharma K.K. NewBridge Pharmaceuticals Lee's Pharmaceutical Holdings Limited
Additional information available to subscribers only: